GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Revvity Inc (NYSE:RVTY) » Definitions » Cyclically Adjusted PS Ratio

Revvity (Revvity) Cyclically Adjusted PS Ratio : 3.63 (As of Apr. 27, 2024)


View and export this data going back to 1983. Start your Free Trial

What is Revvity Cyclically Adjusted PS Ratio?

As of today (2024-04-27), Revvity's current share price is $101.51. Revvity's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $27.95. Revvity's Cyclically Adjusted PS Ratio for today is 3.63.

The historical rank and industry rank for Revvity's Cyclically Adjusted PS Ratio or its related term are showing as below:

RVTY' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.94   Med: 3.9   Max: 7.91
Current: 3.63

During the past years, Revvity's highest Cyclically Adjusted PS Ratio was 7.91. The lowest was 1.94. And the median was 3.90.

RVTY's Cyclically Adjusted PS Ratio is ranked worse than
66.67% of 135 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.21 vs RVTY: 3.63

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Revvity's adjusted revenue per share data for the three months ended in Dec. 2023 was $5.642. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $27.95 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Revvity Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Revvity's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revvity Cyclically Adjusted PS Ratio Chart

Revvity Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.61 6.52 7.91 5.13 3.91

Revvity Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.13 4.80 4.24 3.93 3.91

Competitive Comparison of Revvity's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Revvity's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Revvity's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Revvity's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Revvity's Cyclically Adjusted PS Ratio falls into.



Revvity Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Revvity's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=101.51/27.95
=3.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Revvity's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Revvity's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=5.642/129.4194*129.4194
=5.642

Current CPI (Dec. 2023) = 129.4194.

Revvity Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 4.664 99.695 6.055
201406 4.880 100.560 6.281
201409 4.765 100.428 6.141
201412 3.888 99.070 5.079
201503 4.645 99.621 6.034
201506 4.954 100.684 6.368
201509 4.968 100.392 6.404
201512 4.003 99.792 5.191
201603 4.479 100.470 5.770
201606 4.882 101.688 6.213
201609 4.674 101.861 5.939
201612 5.146 101.863 6.538
201703 4.665 102.862 5.869
201706 4.938 103.349 6.184
201709 4.994 104.136 6.207
201712 5.756 104.011 7.162
201803 5.784 105.290 7.110
201806 6.311 106.317 7.682
201809 6.034 106.507 7.332
201812 6.777 105.998 8.274
201903 5.829 107.251 7.034
201906 6.478 108.070 7.758
201909 6.337 108.329 7.571
201912 7.216 108.420 8.614
202003 5.844 108.902 6.945
202006 7.256 108.767 8.634
202009 8.585 109.815 10.118
202012 2.089 109.897 2.460
202103 11.624 111.754 13.461
202106 10.928 114.631 12.338
202109 7.488 115.734 8.373
202112 8.108 117.630 8.921
202203 7.606 121.301 8.115
202206 7.080 125.017 7.329
202209 5.625 125.227 5.813
202212 5.873 125.222 6.070
202303 5.336 127.348 5.423
202306 5.655 128.729 5.685
202309 5.400 129.860 5.382
202312 5.642 129.419 5.642

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Revvity  (NYSE:RVTY) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Revvity Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Revvity's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Revvity (Revvity) Business Description

Traded in Other Exchanges
Address
940 Winter Street, Waltham, MA, USA, 02451
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Executives
Anita Gonzales officer: Please See Remarks 940 WINTER STREET, REVVITY, WALTHAM MA 02451-1457
Andrew Okun officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Maxwell Krakowiak officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Daniel R Tereau officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Tajinder Vohra officer: Please See Remarks 940 WINTER STREET, WALTHAM MA 02451-1457
Prahlad R. Singh officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 024511457
Joel S Goldberg officer: See Remarks 940 WINTER STREET, WALTHAM MA 02451
Michelle Mcmurry-heath director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 100, DURHAM NC 27703
James M Mock officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451
Sylvie Gregoire director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Miriame Victor officer: Please See Remarks 940 WINTER STREET, PERKINELMER, WALTHAM MA 02451-1457
Peter Barrett director C/O ALNYLAM PHARMACEUTICALS, INC., 300 THIRD STREET, CAMBRIDGE MA 02142
Michel Vounatsos director BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alexis P Michas director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Pascale Witz director C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121